Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.
Microfluidic enrichment of plasma cells improves treatment of multiple myeloma.
复制标题
浆细胞的微流体富集改善了多发性骨髓瘤的治疗
DOI：
10.1002/1878-0261.12201
复制
发表时间：
2018-06
影响因子：
6.6
通讯作者：
Zhong JF
中科院分区：
文献类型：
--
作者：
Zeng Y;Gao L;Luo X;Chen Y;Kabeer MH;Chen X;Stucky A;Loudon WG;Li SC;Zhang X;Zhong JF
细胞遗传学改变构成了多发性骨髓瘤（MM）风险分层的基础，并指导了治疗的选择;然而，由于MM细胞的不可预测的分布和罕见性，目前对骨髓样本进行的病理学检测可能会产生假阴性。在这里，我们报告了一种微流控装置，用于促进CD 45耗竭，以提高检测浆细胞（PC）的细胞遗传学改变。将48例MM患者的骨髓样本各分为两等份。对一份等分试样进行经典流式细胞术和荧光原位杂交（FISH）。另一个首先经历CD 45+细胞去除，通过微流体尺寸选择进一步富集。然后使用流式细胞术和FISH分析富集的样品，并与仅使用经典方法分析的样品进行比较。与传统方法不同的是，微流体装置从剩余的白色血细胞中去除了CD 45+白细胞和专门选择的PC。因此，微流控方法（MF-CD 45-TAC）将骨髓中的CD 38 +/CD 138+细胞百分比从10.3 ± 8.5%显著增加至37.7 ± 20.4%（P < 0.001）。MF-CD 45-TAC富集后，IgH重排、del（13 q14）、del（17 p）和1 q21增加的检出率上升至56.3%（P < 0.001），37.5%分别为22.9%（P <0.001）和41.7%（P = 0.001）;与经典分析样本相比，所有检出率均显著增加。在这项临床试验中，这种微流控辅助测定提供了PC中细胞遗传学改变的精确检测，并改善了临床结果。
Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false‐negatives due to the unpredictable distribution and rarity of MM cells. Here, we report on a microfluidic device used to facilitate CD45 depletion to enhance the detection of cytogenetic alterations in plasma cells (PCs). Bone marrow samples from 48 patients with MM were each divided into two aliquots. One aliquot was subjected to classic flow cytometry and fluorescent in situ hybridization (FISH). The other first went through CD45+ cell depletion, further enriched by microfluidic size selection. The enriched samples were then analyzed using flow cytometry and FISH and compared to those analyzed using the classic method only. Unlike the traditional method, the microfluidic device removed the CD45+ leukocytes and specifically selected PCs from the remaining white blood cells. Therefore, the microfluidic method (MF‐CD45‐TACs) significantly increased the percentage of CD38+/CD138+ cells to 37.7 ± 20.4% (P < 0.001) from 10.3 ± 8.5% in bone marrow. After the MF‐CD45‐TAC enrichment, the detection rate of IgH rearrangement, del(13q14), del(17p), and 1q21 gains, rose to 56.3% (P < 0.001), 37.5% (P < 0.001), 22.9% (P < 0.001), and 41.7% (P = 0.001), respectively; all rates of detection were significantly increased compared to the classically analyzed samples. In this clinical trial, this microfluidic‐assisted assay provided a precise detection of cytogenetic alterations in PCs and improved clinical outcomes.
登录
查看更多内容
影响因子：
2.7
作者：
Gonsalves WI;Timm MM;Rajkumar SV;Morice WG;Dispenzieri A;Buadi FK;Lacy MQ;Dingli D;Leung N;Kapoor P;Kyle RA;Gertz MA;Kumar SK
通讯作者：
Kumar SK
影响因子：
8.9
作者：
Kapoor, Prashant;Fonseca, Rafael;Kumar, Shaji
通讯作者：
Kumar, Shaji
影响因子：
5.2
作者：
Kawano Y;Fujiwara S;Wada N;Izaki M;Yuki H;Okuno Y;Iyama K;Yamasaki H;Sakai A;Mitsuya H;Hata H
通讯作者：
Hata H
影响因子：
11.4
作者：
通讯作者：
--
影响因子：
8.9
作者：
Mikhael, Joseph R.;Dingli, David;Lacy, Martha Q.
通讯作者：
Lacy, Martha Q.